Navigation Links
US WorldMeds Announces the Launch of Revonto™ (dantrolene sodium for injection)
Date:7/6/2010

LOUISVILLE, Ky., July 6 /PRNewswire/ -- US WorldMeds is proud to announce the launch of Revonto™ (dantrolene sodium for injection), the first patented scientific advancement in the treatment of malignant hyperthermia (MH).  The time to reconstitute dantrolene sodium for injection has been dramatically reduced to approximately 20 seconds or until the solution is clear.  Revonto™ retains the cost-savings of the original dantrolene sodium for injection product while offering a significant improvement in pharmacotherapy.

"The enhanced reconstitution time is an important and critical scientific improvement to intravenous dantrolene sodium, the only available antidote for the treatment of malignant hyperthermia.  MH is triggered in some patients by certain inhalation anesthetics during surgery.  A rapid response to MH onset is critical because temperatures exceeding 105F degrees and death due to this condition can occur as early as 30 minutes from onset." says Dr. George A. Digenis, Chief Scientific Officer of US WorldMeds.

Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy.  There have been reports of thrombophlebitis following administration of intravenous dantrolene.  There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. dantrolene sodium. For additional information, including the full prescribing information for Revonto™, please visit US WorldMeds' website at www.revonto.com.

For more information on malignant hyperthermia, please visit The Malignant Hyperthermia Association of the United States (MHAUS) website at www.mhaus.org

Revonto™ will be available on GPO contracts as a dropship via your wholesaler/distributor.

For Ordering Information Call: 1.877.411.USWM(8796).

About US WorldMeds

US WorldMeds, LLC, a specialty pharmaceutical company located in Louisville, Kentucky, is committed to developing, licensing, and marketing unique and significant pharmaceuticals that address unmet medical needs. US WorldMeds is committed to using science to make lives better. For more information, please visit www.usworldmeds.com


'/>"/>
SOURCE US WorldMeds
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Second Quarter 2010 Results
3. Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin®
4. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
5. PolyTouch Medical Ltd. Announces the Appointment of Robert D. Fanelli, MD, FACS, FASGE as Medical Advisor
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7. ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
8. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
9. Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
10. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
11. Sysmex America Announces Executive Leadership Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):